Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Pharmacokinetics of bendroflumethiazide in hypertensive patients

  • 56 Accesses

  • 9 Citations


After four weeks on placebo treatment, 8 hypertensive patients (WHO stage I) were treated for 2 weeks with bendroflumethiazide (bft) 2.5 mg and KCl 1.5 g daily. Subsequently they received bft 5 mg and KCl 1.5 g daily for a further fortnight. At the end of each period of treatment blood pressure was recorded and blood samples and urine were collected for analysis of bft by GLC. Before taking the daily dose of bft, no trace of the drug was found in plasma. Peak levels of bft were seen after 2.3 h and averaged 23 and 50 ng · ml−1 after 2.5 and 5 mg, respectively. After bft 2.5 mg the plasma level was too low for kinetic analysis. The plasma half-life after 5 mg averaged 4.1 h. The mean apparent volume of distribution was 1.18 l · kg−1. Non-renal clearance averaged 200 ml · min−1. The renal clearance of bft was significantly lower (p<0.05) after 5 mg (48 ml · min−1) than after 2.5 mg bft (93 ml · min−1), although the creatinine clearance remained unchanged. No correlation was found between the plasma level of bft and its effect on blood pressure.

This is a preview of subscription content, log in to check access.


  1. 1.

    Beermann, B., Gronschinsky-Grind, M. Lindström, B.: A GLC assay for bendroflumethiazide. Preliminary data about its levels in man. Europ. J. clin. Pharmacol.10, 293–295 (1976)

  2. 2.

    Beermann, B., Gronschinsky-Grind, M., Lindström, B.: On the pharmacokinetics of bendroflumethiazide in man. Clin. Pharm. Ther.22, 385–388 (1977)

  3. 3.

    Bengtsson, C., Johnsson, G., Sannerstedt, R., Werkö, L.: Effect of different doses of chlorthalidone on blood pressure, serum potassium and serum urate. Brit. med. J.1975/3, 197–199

  4. 4.

    Berglund, G. & O. Andersson: Low doses of hydrochlorothiazide in hypertension. Antihypertensive and metabolic effects. Europ. J. clin. Pharmacol.,10, 177–182 (1976)

  5. 5.

    Bretell, H. R., Smith, J. G., Aikowa, J. K.: S35-labelled bendroflumethiazide in human beings. Arch. Int. Med.113, 373–377 (1964)

  6. 6.

    Castles, T. R., Williamson: The effect of chlorothiazide on the excretion of uric acid and electrolytes by the chicken. J. Pharmacol. exp. Ther.142, 231–236, (1963)

Download references

Author information

Additional information

Supported by the Swedish Medical Research Council (Grant No. B77-19X-00227-13) and Ferrosan AB, Malmö, Sweden.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Beermann, B., Groschinsky-Grind, M., Lindström, B. et al. Pharmacokinetics of bendroflumethiazide in hypertensive patients. Eur J Clin Pharmacol 13, 119–124 (1978). https://doi.org/10.1007/BF00609755

Download citation

Key words

  • Bendroflumethiazide
  • pharmacokinetics
  • hypertension
  • renal clearance